Appetite
Reduced hunger, fewer cravings and earlier fullness may make it easier to eat smaller portions.
SlimTheory medication guide
A simple guide to the three pathways.
This overview explains the basic differences between semaglutide, tirzepatide and retatrutide. Applicants receive more detailed information during SlimTheory matriculation.
Start with the basics
What do these pathways have in common?
Digestion
Slower stomach emptying can extend fullness but may also contribute to gastrointestinal side effects.
Blood sugar
These pathways can influence insulin response and glucose regulation.
Progress
Results vary. Medication choice, dose, consistency, tolerance and individual biology all matter.
At a glance
Single, dual and triple pathway.
More pathways do not automatically make one option best for everyone. People can respond differently to each medication.
01
Single pathway
SemaSlim™
Semaglutide
GLP-1The most established of the three pathways, with a long clinical track record in blood-sugar regulation and chronic weight management.
How it works
It activates the GLP-1 receptor, helping reduce hunger, increase feelings of fullness and slow digestion.
What stands out
- One hormone pathway
- Often described as steady and gradual
- The longest-established option in this comparison
SlimTheory provides a compounded form of semaglutide.
02
Dual pathway
TirzTheory™
Tirzepatide
GIP + GLP-1A dual-pathway option that combines GLP-1 activity with GIP activity for additional appetite and metabolic effects.
How it works
It activates both GIP and GLP-1 receptors, which influence appetite, fullness, insulin response and blood-sugar regulation.
What stands out
- Two hormone pathways
- Strong appetite regulation for many people
- May produce greater average weight loss than single-pathway therapy
SlimTheory provides a compounded form of tirzepatide.
03
Triple pathway
TriReta™
Retatrutide
GIP + GLP-1 + glucagonA newer triple-agonist being studied for its combined effects on appetite, metabolic regulation and energy use.
How it works
It activates GIP, GLP-1 and glucagon receptors. The added glucagon pathway is being studied for its potential effects on energy expenditure and fat metabolism.
What stands out
- Three hormone pathways
- Promising results in clinical trials
- Less long-term real-world information is available
Retatrutide remains investigational and is not FDA-approved.
SlimTheory provides compounded medications. Compounded medications are not FDA-approved. Learn more from the FDA.
Choosing a pathway
There is no universal “best.”
Goals, medication history, tolerance and health information can all affect which options may be appropriate.
Your goals
Think about what you hope to achieve and the pace of change you are comfortable with.
Your experience
Previous experience with GLP-based medications can help provide context for your options.
Your tolerance
Side effects and response can differ between medications. A stronger effect is not always a better experience.
Your screening
The health screening helps identify safety concerns before enrollment options are presented.
Good to know
The basics before beginning.
Side effects can happen
Nausea, vomiting, diarrhea, constipation, stomach discomfort, fatigue and dizziness are among the commonly reported effects. Experiences vary from person to person.
Screening matters
These medications are not appropriate for everyone. SlimTheory requires a health screening before enrollment options are presented.
Know when to seek care
Severe, persistent or concerning symptoms should be addressed promptly with an appropriate healthcare professional.
For general education
A simple introduction before matriculation.
This guide does not determine eligibility, recommend a medication or replace advice from your healthcare professional. Applicants receive more detailed information during SlimTheory matriculation.
Learn more about retatrutide from Eli Lilly and the published phase 2 trial.
When you’re ready